- Report
- March 2026
- 191 Pages
Global
From €5242EUR$5,850USD£4,544GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,488GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£971GBP
- Report
- October 2025
- 160 Pages
Global
From €3540EUR$3,950USD£3,068GBP
- Report
- October 2025
- 160 Pages
Global
From €3540EUR$3,950USD£3,068GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,184USD£3,140GBP
- Report
- January 2026
- 196 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- August 2025
- 180 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- March 2026
- 291 Pages
Global
From €5242EUR$5,850USD£4,544GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,488GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£971GBP
- Report
- July 2025
- 155 Pages
Global
From €4167EUR$4,650USD£3,612GBP
- Report
- May 2025
- 150 Pages
Global
From €5332EUR$5,950USD£4,622GBP
- Report
- January 2026
- 199 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- January 2026
- 193 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- January 2026
- 184 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- January 2026
- 194 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- January 2026
- 197 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- January 2026
- 182 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- January 2026
- 191 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more